News & Updates

Digital health technologies (DHTs) can help lower healthcare utilization and costs but appear to have not enough juice to reduce the risk of relapse, improve quality of life (QoL), and increase treatment adherence in patients with inflammatory bowel disease (IBD), according to a study.

There appears to be a higher prevalence of gastrointestinal (GI) symptoms in hospitalized patients with COVID-19 than previously reported, reveals a recent study.

The benefits of the 5:2 diet – which involves limited caloric intake (500–600 kcal) for 2 nonconsecutive days per week only – mirrored those achieved with a multicomponent weight management advice, according to a UK study on adults with obesity. However, the benefits eventually waned, even when intensified with group support.

The coronavirus disease 2019 (COVID-19) pandemic has led to a sharp decline in treatment for older patients with newly diagnosed cancers of the digestive system, a recent study has found.

Treatment intensification is needed in around one-third of biologic-naïve patients with inflammatory bowel disease (IBD) who had received initial antitumour necrosis factor α (anti-TNFα) medication, a recent study has found.

The combination of cabozantinib and atezolizumab in the first-line setting significantly improved progression-free survival (PFS) compared with sorafenib in patients with advanced hepatocellular carcinoma (HCC), according to results of the phase III COSMIC-312 trial presented at ESMO Asia 2021.